Curriculum Vitae

2005-2006 Advanced Fellowship in Inflammatory Bowel Disease Cedars-Sinai Medical Centre, Los Angeles California 2002-2004 Fellowship in Gastroenterology, University of Calgary 1999-2000 Residency in Internal Medicine, University of Calgary 1995-1999 Doctor of Medicine, University of Manitoba 1991-1995 Bachelors of Science, Zoology

Clinical/Research Interests

Dr. Devlin specializes in Inflammatory Bowel Disease research and is an active member of the clinical trial unit

Publications

Patient-specific approach to combination versus monotherapy with the use of antitumor necrosis factor α agents for inflammatory bowel disease Devlin SM, Cheifetz AS, Siegel CA; BRIDGe group. Gastroenterol Clin North Am. 2012 Jun;41(2):411-28.

Assessment of variables associated with smoking cessation in Crohn's disease. Leung Y, Kaplan GG, Rioux KP, Hubbard J, Kamhawi S, Stasiak L, Cohen RD, Devlin SM, Panaccione R, Hanauer SB, Rubin DT. Dig Dis Sci. 2012 Apr;57(4):1026-32.

Optimizing the safety of biologic therapy for IBD. de Silva S, Devlin S, Panaccione R.Nat Rev Gastroenterol Hepatol. 2010 Feb;7(2):93-101.

The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all. Melmed GY, Spiegel BM, Bressler B, Cheifetz AS, Devlin SM, Harrell LE, Irving PM, Jones J, Kaplan GG, Kozuch PL, Velayos FS, Baidoo L, Sparrow MP, Siegel CA. Clin Gastroenterol Hepatol 2010;8(8):655-9.